Newsfeeds Archive - Spark Newswire

1 minute read

Why Is Life Sciences-Focused Aditxt Stock Trading Higher Today?

December 12, 11:18 AM

Aditxt Inc (NASDAQ: ADTX) has agreed to acquire Evofem Biosciences Inc (OTC: EVFM) in consideration of the issuance of a combination of common stock and preferred stock and the assumption of certain senior i

ADTX

5 minute read

Aditxt, Inc. Enters Into Definitive Agreement To Acquire Evofem Biosciences For Consideration Of The Issuance Of A Combination Of Common Stock And Preferred Stock, And The Assumption Of Certain Senior Indebtedness, Having An Aggregate Amount Of ~$100M

By Benzinga Newsdesk

December 12, 9:34 AM

Evofem posted $13.4 million in net sales of Phexxifor the first nine months of 2023;Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to

ADTX

1 minute read

Stifel Downgrades Evofem Biosciences to Hold, Lowers Price Target to $0.5

By Benzinga Newsdesk

October 13, 5:38 AM

Stifel analyst Annabel Samimy downgrades Evofem Biosciences (OTC:EVFM) from Buy to Hold and lowers the price target from $3 to $0.5.

EVFM

1 minute read

Why Evofem Biosciences Shares Are Plunging Today?

By Vandana Singh

October 12, 2:17 PM

Evofem Biosciences Inc's (OTC: EVFM) recently completed the Phase 3 EVOGUARD trial evaluating Phexxi vaginal gel (EVO100) to prevent chlamydia and gonorrhea infection in women but did not achieve its endpoints.

EVFM

2 minute read

Evofem Announces Issuance Of U.S. Patent Covering Phexxi Composition Of Matter; Newly Issued Patent Expected To Provide Protection For Phexxi Into At Least 2033

By Benzinga Newsdesk

September 23, 9:02 AM

-- Issuance of U.S. Patent No. 11,439,610 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly Issued Patent Expected to Provide Protection for Phexxi into At Least 2033 -- SAN

EVFM

1 minute read

News

‘West Virginia governor signs abortion ban, making state the second to enact abortion restrictions since Roe overturned.’ – Tweet By Zeke Miller

By Benzinga Newsdesk

September 16, 1:48 PM

https://twitter.com/ZekeJMiller/status/1570831511469060096

AGRX

2 minute read

Analyst Ratings

4 Analysts Have This to Say About Evofem Biosciences

By Benzinga Insights

August 15, 10:10 AM

Over the past 3 months, 4 analysts have published their opinion on Evofem Biosciences (OTC:EVFM) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

EVFM

8 minute read

Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday

By Lisa Levin

August 11, 5:28 AM

Gainers Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.

ABCL

9 minute read

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday

By Lisa Levin

August 10, 3:52 AM

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method.

AEL

6 minute read

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday’s Mid-Day Session

By Lisa Levin

August 9, 1:26 PM

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The company also reported Q2 earnings results.

AEL